Goldman Sachs Downgrades Amylyx Pharma to Neutral, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Chris Shibutani downgraded Amylyx Pharma (NASDAQ:AMLX) from Buy to Neutral and significantly reduced the price target from $40 to $4, indicating a bearish outlook on the company's stock.

March 11, 2024 | 1:22 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Goldman Sachs downgraded Amylyx Pharma from Buy to Neutral and lowered the price target from $40 to $4, showing a negative outlook.
The downgrade by a prominent analyst like Goldman Sachs, coupled with a drastic reduction in the price target, is a strong bearish signal. This suggests that the analyst has significant concerns about the company's future performance or valuation, which could lead to a decrease in investor confidence and a potential drop in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100